Nuvectis intends to use the net proceeds from the offering to continue to advance the development programs of NXP800 and NXP900 or any future product candidate, hiring of additional personnel, capital expenditures, costs of operating as a public company and other general corporate purposes.

RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and commercializing

Nuvectis Pharma (NVCT) announced the pricing of its previously announced underwritten public offering of 2,700,000 shares of its common stock at a

Prairie Operating Co. (“Prairie” or the “Company”) (Nasdaq: PROP), an independent oil and gas company focused on the acquisition and development of crude oil, natural gas and natural gas liquids, announced today that it has commenced an underwritten public offering of $200 million of shares of its common stock,

Glucot (Nasdaq: GCTK), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced the pricing of a “best efforts” public offering of approximately 2.

Volcon, Inc. (NASDAQ:VLCN) (the “Company”), the first all-electric, off-road powersports company, today announced the pricing of a firm commitment underwritten public offering with gross proceeds to the

Neuronetics shares were down 12% to $3.15 after the company priced a previously announced $18 million, underwritten public offering. The neuroscience company said the offering is comprised of 8 million shares of stock at $2.

Neuronetics (STIM) has priced its previously announced underwritten public offering of its common stock, comprised of 8,000,000 shares of